Brandon Capital Announces Agreement for Novartis to Acquire Portf

{
  "signal_id": "7b8d6b41-dac9-5e89-15a8-a3918ac34f9e",
  "signal_type": "news",
  "signal_subtype": "acquires",
  "detected_at": "2026-07-06T06:08:14+00:00",
  "company": {
    "name": "Novartis",
    "domain": "novartis.com"
  },
  "data": {
    "url": "https://natlawreview.com/press-releases/brandon-capital-announces-agreement-novartis-acquire-portfolio-company",
    "title": "Brandon Capital Announces Agreement for Novartis to Acquire Portf - The National Law Review",
    "excerpt": "MELBOURNE, Australia, July 06, 2026 (GLOBE NEWSWIRE) -- Brandon Capital, Australasia’s leading life sciences venture capital firm, today announces the successful exit of its portfolio company Myricx Bio following its agreement to be acquired by Novartis. The transaction is valued at up to US$1.5 billion (~A$2.16bn) including an upfront cash payment of US$1.1 billion (~A$1.58bn) plus potential milestone payments. Myricx Bio is a UK-based pre-clinical oncology company developing a novel class of payloads for antibody-drug conjugates (ADCs). One of the most important emerging modalities in cancer therapy, ADCs combine the targeting precision of antibodies with the tumour-killing activity of potent small-molecule payloads. The acquisition advances ADC innovation by bringing together the strengths of Novartis in oncology with Myricx’s two lead ADC assets and its next-generation N-myristoyltransferase inhibitor (NMTi) payload platform with potential impact across multiple solid tumour settings. Brandon Capital played an instrumental role in the formation of Myricx Bio, a spin out from Imperial College London and the Francis Crick Institute. It was co-founded by Brandon Capital Venture Partner Dr. Roberto Solari who served as Myricx Bio’s founding CEO. Brandon Capital was joint founding seed investor in 2019. Managing Partner Dr. Stephen Thompson led the investment, providing...",
    "summary": "Novartis has agreed to acquire UK-based pre-clinical oncology company Myricx Bio in a transaction valued at up to US$1.5 billion.",
    "location": "United Kingdom",
    "planning": false,
    "confidence": 1,
    "published_at": "2026-07-06T06:08:14Z",
    "location_data": [
      {
        "state": "England",
        "region": "Northern Europe",
        "country": "United Kingdom",
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "Brandon Capital, Australasia’s leading life sciences venture capital firm, today announces the successful exit of its portfolio company Myricx Bio following its agreement to be acquired by Novartis.",
    "amount_normalized": 1500000000,
    "related_company_name": "Myricx Bio",
    "related_company_domain": "myricxbio.com"
  }
}

curl https://signals.autobound.ai/v1/signals/7b8d6b41-dac9-5e89-15a8-a3918ac34f9e \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"novartis.com","limit":20}'